Treatment of neurocysticercosis: A review;Tratamiento de la neurocisticercosis: Revisión critica

Revista Medica de Chile

Volumn 134, Issue 6, 2006, Pages 789-796

  Nogales Gaete, Jorge ^a,d   Arriagada R, Camilo ^b   Salinas R, Rodrigo ^c  

^a UNIVERSITY OF CHILE   (Chile)

^b HOSPITAL DEL TRABAJADOR   (Chile)

^c Ministerio de Salud de Chile   (Chile)

^d NONE   (Chile)

Author keywords

Albendazole; Neurocysticercosis; Praziquantel; Treatment

Indexed keywords

EID: 33746848103     PISSN: 00349887     EISSN: 07176163     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. BRINK G, SCHENONE H, DÍAZ V, PARRA M, CORRALES M. Neurocisticercosis: tratamiento con praziquantel. Estudio preliminar. Bol Chil Parasitol 1980; 35: 66-70.
2. ALARCÓN F, ESCALANTE L, DUEÑAS G, MONTALVO M, ROMÁN M. Neurocysticercosis: short course of treatment with albendazole. Arch Neurol 1989; 46: 1231-6.
3. ESCOBEDO F, PENAGOS P, RODRÍGUEZ J, SOTELO J. Albendazole therapy for neurocysticercosis. Arch Intern Med 1987; 147: 738-41.
4. CRUZ-ULTRERAS I, CRUZ M. Tratamiento médico de la neurocisticercosis. En: Arriagada C, Nogales-Gaete J, Apt W, eds. Neurocisticercosis. Santiago: ARRYNOG 1997; 287-98.
5. PROAÑO JV, MADRAZO I, GARCÍA L, GARCÍA-TORRES E, CORREA D. Albendazole and praziquantel treatment in neurocysticercosis of the fourth ventricle. J Neurosurg 1997; 87: 29-33.
6. PROAÑO JV, MADRAZO I, AVELAR F, LÓPEZ-FÉLIX B, DÍAZ G, GRIJALVA I. Medical treatment for neurocysticercosis characterized by giant subarachnoid cysts. N Engl J Med 2001; 345: 879-85.
7. GARCÍA HH, EVANS CA, NASH TE, TAKAYANAGUI OM, WHITE AC JR, BOTERO D ET AL. Current consensus guidelines for treatment of neurocysticercosis. Clin Microbiol Rev 2002; 15: 747-56.
8. GARCÍA H, GONZÁLEZ A, EVANS C, GILMAN R. Taenia solium cysticercosis. Lancet 2003; 361: 547-56.
9. KALRA V, DUA T, KUMAR V. Efficacy of albendazole and short-course dexamethasone treatment in children with 1 or 2 ring-enhancing lesions of neurocysticercosis: a randomized controlled trial. J Pediatr 2003; 143: 111-4.
10. NASH T. Human case management and treatment of cysticercosis. Acta Tropica 2003; 87: 61-9.
11. GARCÍA HH, PRETELL EJ, GILMAN RH, MARTÍNEZ SM, MOULTON LH, DEL BRUTTO OH ET AL. A trial of antiparasitic treatment to reduce the rate of seizures due to cerebral cysticercosis. N Engl J Med 2004; 350: 249-58.
12. NOGALES-GAETE J, ARRIAGADA C, GONZÁLEZ J. Síndromes anátomo-clínicos de la neurocisticercosis. En: Arriagada C, Nogales-Gaete J, Apt W, eds. Neurocisticercosis. Santiago: ARRYNOG 1997; 117-38.
13. ARRIAGADA C, NOGALES-GAETE J, MATUS C. [Pathology of neurocysticercosis]. En: Arriagada C, Nogales-Gaete J, Apt W, eds. Neurocisticercosis. Santiago: ARRYNOG 1997; 53-115.
14. ARRIAGADA V, ARRIAGADA C, TERRA E, MANEN R, JULIO D. Imagen de resonancia magnética (IRM) en neurocisticercosis. En: Arriagada C, Nogales-Gaete J, Apt W, eds. Neurocisticercosis. Santiago: ARRYNOG 1997; 209-78.
15. NOGALES-GAETE J, ARRIAGADA C, CARRASCO X, GONZÁLEZ J, CHÁVEZ A. Neurocisticercosis como paradigma de las parasitosis del sistema nervioso central. En: Nogales-Gaete J, Donoso A, Verdugo R, eds. Tratado de Neurología Clínica. Santiago: Ediciones Sonepsyn - Editorial Universitaria 2005; 363-74.
16. nd ed New York: Churchill Livingstone; 2000.
17. LEE K, MILLS A. Strengthening governance for global health research. BMJ 2000; 321: 775-6.
18. SALINAS R, COUNSELL C, PRASAD K, GELBAND H, GARNER P. Treating neurocysticercosis medically: a systematic review of randomized, controlled trials. Trop Med Int Health 1999; 4: 713-8.
19. SALINAS R, PRASAD K. Drugs for treating neurocysticercosis (tapeworm infection of the brain). Cochrane Database Syst Rev. 2000: CD000215.
20. SARTI E. Taeniosis y cisticercosis en México. En: Arriagada C, Nogales-Gaete J, Apt W, eds. Neurocisticercosis. Santiago: ARRYNOG 1997; 5-22.
21. CARPIO A. Neurocysticercosis: an update. Lancet Infect Dis 2002; 2: 751-62.
22. TORRES M, PÉREZ C, GALDÁMEZ E, GABOR M, MIRANDA C, COFRÉ X ET AL. Teniosis: serie clínica en 35 pacientes. Parasitol día 2001; 25: 55-9.
23. GILMAN RH, DEL BRUTTO OH, GARCÍA HH, MARTÍNEZ M. Prevalence of taeniosis among patients with neurocysticercosis is related to severity of infection. The Cysticercosis Working Group in Peru. Neurology 2000; 55: 1062.
24. SCHANTZ PM, MOORE AC, MUNOZ JL, HARTMAN BJ, SCHAEFER JA, ARON AM ET AL. Neurocysticercosis in an Orthodox Jewish community in New York City. N Engl J Med 1992; 327: 692-5.
25. ROMÁN G, SOTELO J, DEL BRUTTO O, FLISSER A, DUMAS M, WADIA N ET AL. A proposal to declare neurocysticercosis an international reportable disease. Bull World Health Organ 2000; 78: 399-406.
26. GARCÍA H, GONZÁLEZ A, GILMAN R. Diagnosis, treatment and control of Taenia solium cysticercosis. Curr Opin Infect Dis 2003; 16: 411-9.
27. PLANCARTE A, FLISSER A, GAUCI CG, LIGHTOWLERS MW. Vaccination against Taenia solium cysticercosis in pigs using native and recombinant oncosphere antigens. Int J Parasitol 1999; 29: 643-7.
28. RILEY T, WHITE AC JR. Management of neurocysticercosis. CNS Drugs 2003; 17: 577-91.
29. PADMA MV, BEHARI M, MISRA NK, AHUJA GK. Albendazole in single CT ring lesions in epilepsy. Neurology 1994; 44: 1344-6.
30. MADRAZO I, PROAÑO J. Tratamiento quirúrgico de la neurocisticercosis. En: Arriagada C, Nogales-Gaete J, Apt W, eds. Neurocisticercosis. Santiago: ARRYNOG 1997; 299-321.
31. CITOW J, JOHNSON P, MC BRIDE D, AMMIRATI M. Imaging features and surgery-related outcomes in intraventricular neurocysticercosis. Neurosurg Focus (e-journal) 2002; 12: Disponible en URL http://www.medscape.com/ viewpublication/65_toc?vol=12&iss=6.
32. CUETTER A, ANDREWS R. Intraventricular neurocysticercosis: 18 consecutive patients and review of the literature. Neurosurg Focus (e-journal) 2002; 12 (6): Disponible en URL http://www.medscape.com/viewpublication/65_toc?vol= 12&iss=6.
33. KELLEY R, DUONG D, LOCKE G. Characteristics of Ventricular Shunt Malfunctions among patients with Neurocysticercosis. Neurosurgery 2002; 50: 757-62.
34. DEL BRUTTO O, SOTELO J. Albendazole therapy for subarachnoid and ventricular cysticerciosis. J Neurosurgery 1990; 62: 816-7.
35. BARINAGARREMENTERÍA F, CANTÚ C. Arteritis cerebral cisticercosa. En: Arriagada C, Nogales-Gaete J, Apt W, eds. Neurocisticercosis. Santiago: ARRYNOG 1997; 139-52.
36. CANTÚ C, BARINAGARREMENTERÍA F. Cerebrovascular complications of neurocysticercosis: Clinical and neuroimaging spectrum. Arch Neurol 1966; 53: 233-9.
37. COLLI B, MORAES M, CARLOTTI C, RUBENS H, ASSIRATI J. Spinal cord cysticercosis: neurosurgical aspects. Neurosurg Focus (e-journal) 2002; 12 (6): Disponible en URL http://www.medscape.com/viewpublication/65_toc?vol=12&iss= 6.
38. GARG RK. Medical management of neurocysticercosis. Neurol India 2001; 49: 329-37.
39. PÉREZ-LÓPEZ C, ISLA-GUERRERO A, ALVAREZ F, BUDKE M, FERNÁNDEZ-MIRANDA J, PAZ J ET AL. Actualización en el tratamiento de la neurocisticercosis. Rev Neurol 2003; 36: 805-11.
40. SUASTEGUI ROMÁN RA, SOTO-HERNÁNDEZ JL, SOTELO J. Effects of prednisone on ventriculoperitoneal shunt function in hydrocephalus secondary to cysticercosis: a preliminary study. J Neurosurg 1996; 84: 629-33.